PulseAugur
EN
LIVE 20:56:45
中文(ZH) 复星医药：控股子公司帕妥珠单抗注射液上市注册申请获批

Fosun Pharma subsidiary's breast cancer drug approved in China

By PulseAugur Editorial · [1 sources] ·

Fosun Pharma announced that its subsidiary, Shanghai Fosun Pharmaceutical Biotechnology Co., Ltd., has received approval from China's National Medical Products Administration for its Pertuzumab Injection. This approval covers all indications for which the originator drug is approved in China, including early-stage and metastatic breast cancer. Separately, Xiamen Tungsten announced that its subsidiary, Jinlong Rare Earth, plans to list on the Beijing Stock Exchange, aiming to raise capital for projects focused on rare earth permanent magnet materials. AI

IMPACT N/A

RANK_REASON Regulatory approval of a new drug for cancer treatment. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Fosun Pharma subsidiary's breast cancer drug approved in China

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Regulatory approval of a new drug for cancer treatment. [lever_c_demoted from significant: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, policy
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
102 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Fosun Pharma: Marketing registration application for subsidiary Pertuzumab Injection approved

    36氪获悉，复星医药公告，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的帕妥珠单抗注射液的上市注册申请获国家药监局批准，此次获批适应症覆盖原研帕妥珠单抗注射液于中国境内已获批的所有适应症，包括早期乳腺癌以及转移性乳腺癌。

RELATED ENTITIES

RELATED TOPICS